Alessandro Riva
Chief Executive Officer bij TRANSGENE
Vermogen: 949 786 $ op 29-02-2024
Profiel
Alessandro Riva founded Cancer International Research Group and Breast Cancer International Research Group Ltd.
Presently, Dr. Riva is Chief Executive Officer of Intima Bioscience, Inc. and Chairman & Chief Executive Officer of Transgene SA. Dr. Riva is also on the board of BeiGene Ltd.
and Century Therapeutics, Inc.
In the past Alessandro Riva held the position of Director at Ichnos Sciences, Inc., Executive VP-Oncology Therapeutics at Gilead Sciences, Inc., VP, Head-Oncology Development & Medical Affairs at Novartis AG President at Novartis Oncology, Inc. and EVP, Head-Oncology Development & Medical Affairs at Novartis Pharmaceuticals Corp.
(both are subsidiaries of Novartis AG) and Chief Executive Officer-Innovation Business at Glenmark Pharmaceuticals Ltd.
He received a doctorate and an undergraduate degree from the University of Milan.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
BEIGENE LTD
0.01% | 15-06-2023 | 70 148 ( 0.01% ) | 949 786 $ | 29-02-2024 |
27-06-2023 | 0 ( -.--% ) | - $ | 29-02-2024 |
Actieve functies van Alessandro Riva
Bedrijven | Functie | Begin |
---|---|---|
BEIGENE, LTD. | Director/Board Member | 01-02-2022 |
CENTURY THERAPEUTICS, INC. | Director/Board Member | 01-05-2021 |
TRANSGENE | Chief Executive Officer | 01-06-2023 |
Intima Bioscience, Inc.
Intima Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Intima Bioscience, Inc. is a bioscience company that is advancing checkpoint cell therapy for solid tumors with curative intent. The private company is based in New York, NY. The company combines the use of patients' own immune cells with immune checkpoint targeting. Intima is currently running a phase 1/2 clinical study of its checkpoint cell therapy, which targets the immune checkpoint cish in patients with gastrointestinal and colon cancers. Alessandro Riva has been the CEO of the company since 2021. | Chief Executive Officer | 01-09-2021 |
Eerdere bekende functies van Alessandro Riva
Bedrijven | Functie | Einde |
---|---|---|
Ichnos Sciences, Inc.
Ichnos Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ichnos Sciences, Inc. operates as a biotechnology company. It provides curative therapies that extend human life. The company was founded in 2019 and is headquartered in Paramus, NJ. | Chief Executive Officer | 21-05-2021 |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | 06-03-2019 |
NOVARTIS AG | Corporate Officer/Principal | 01-12-2016 |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | President | 01-01-2016 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01-01-2016 |
Opleiding van Alessandro Riva
University of Milan | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 6 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
TRANSGENE | Health Technology |
NOVARTIS AG | Health Technology |
GLENMARK PHARMACEUTICALS LIMITED | Health Technology |
BEIGENE, LTD. | Health Technology |
CENTURY THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 7 |
---|---|
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Breast Cancer International Research Group Ltd. | |
Intima Bioscience, Inc.
Intima Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Intima Bioscience, Inc. is a bioscience company that is advancing checkpoint cell therapy for solid tumors with curative intent. The private company is based in New York, NY. The company combines the use of patients' own immune cells with immune checkpoint targeting. Intima is currently running a phase 1/2 clinical study of its checkpoint cell therapy, which targets the immune checkpoint cish in patients with gastrointestinal and colon cancers. Alessandro Riva has been the CEO of the company since 2021. | Health Technology |
Ichnos Sciences, Inc.
Ichnos Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ichnos Sciences, Inc. operates as a biotechnology company. It provides curative therapies that extend human life. The company was founded in 2019 and is headquartered in Paramus, NJ. | Commercial Services |
Century Therapeutics, Inc. /Old/
Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
Cancer International Research Group |